Northern Trust Corp Has $12.10 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Northern Trust Corp grew its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 7.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 631,131 shares of the company's stock after purchasing an additional 42,638 shares during the period. Northern Trust Corp owned approximately 0.92% of Arvinas worth $12,099,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ARVN. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arvinas during the fourth quarter valued at approximately $42,332,000. Norges Bank bought a new stake in shares of Arvinas in the fourth quarter worth $23,845,000. Affinity Asset Advisors LLC increased its stake in shares of Arvinas by 180.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 630,000 shares of the company's stock worth $12,077,000 after buying an additional 405,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Arvinas by 6.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after buying an additional 249,295 shares during the last quarter. Finally, BIT Capital GmbH increased its stake in shares of Arvinas by 291.7% in the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company's stock worth $5,052,000 after buying an additional 196,246 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Buying and Selling

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This represents a 2.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. The trade was a 7.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 over the last 90 days. 4.73% of the stock is currently owned by company insiders.

Arvinas Stock Performance

Shares of ARVN traded up $0.22 during midday trading on Thursday, hitting $6.47. 2,039,375 shares of the stock traded hands, compared to its average volume of 1,333,835. The firm has a market capitalization of $472.25 million, a PE ratio of -2.34 and a beta of 2.21. The business's 50 day moving average price is $7.52 and its two-hundred day moving average price is $15.55. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $36.20.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The firm's quarterly revenue was up 646.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.97) earnings per share. As a group, equities research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ARVN. BMO Capital Markets dropped their price target on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research note on Monday, May 5th. Citigroup dropped their price target on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research note on Monday, May 5th. Guggenheim dropped their price target on shares of Arvinas from $32.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Truist Financial reaffirmed a "hold" rating and issued a $11.00 price objective (down previously from $21.00) on shares of Arvinas in a report on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price objective on shares of Arvinas from $12.00 to $8.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $20.92.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.